Saumya R Bollam1, Michael E Berens1, Harshil D Dhruv2. 1. Division of Cancer and Cell Biology, Translational Genomics Research Institute, 445 N 5th Street, Phoenix, AZ, 85004, USA. 2. Division of Cancer and Cell Biology, Translational Genomics Research Institute, 445 N 5th Street, Phoenix, AZ, 85004, USA. hdhruv@tgen.org.
Abstract
PURPOSE OF REVIEW: High-throughput genomic sequencing has identified alterations in the gene encoding human telomerase reverse transcriptase (TERT) as points of interest for elucidating the oncogenic mechanism of multiple different cancer types, including gliomas. In gliomas, the TERT promoter mutation (TPM) and resultant overexpression of TERT are observed mainly in the most aggressive (primary glioblastoma/grade IV astrocytoma) and the least aggressive (grade II oligodendroglioma) cases. This article reviews recent research on (1) the mechanism of TERT activation in glioma, (2) downstream consequences of TERT overexpression on glioma pathogenesis, and (3) targeting TPMs as a therapeutic strategy. RECENT FINDINGS: New molecular classifications for gliomas include using TPMs, where the mutant group demonstrates the worst prognosis. Though a canonical function of TERT is established in regard to telomere maintenance, recent studies on non-canonical functions of TERT explore varied roles of telomerase in tumor progression and maintenance. Somatic alterations of the TERT promoter present a promising target for novel therapeutics development in primary glioma treatment.
PURPOSE OF REVIEW: High-throughput genomic sequencing has identified alterations in the gene encoding humantelomerase reverse transcriptase (TERT) as points of interest for elucidating the oncogenic mechanism of multiple different cancer types, including gliomas. In gliomas, the TERT promoter mutation (TPM) and resultant overexpression of TERT are observed mainly in the most aggressive (primary glioblastoma/grade IV astrocytoma) and the least aggressive (grade II oligodendroglioma) cases. This article reviews recent research on (1) the mechanism of TERT activation in glioma, (2) downstream consequences of TERT overexpression on glioma pathogenesis, and (3) targeting TPMs as a therapeutic strategy. RECENT FINDINGS: New molecular classifications for gliomas include using TPMs, where the mutant group demonstrates the worst prognosis. Though a canonical function of TERT is established in regard to telomere maintenance, recent studies on non-canonical functions of TERT explore varied roles of telomerase in tumor progression and maintenance. Somatic alterations of the TERT promoter present a promising target for novel therapeutics development in primary glioma treatment.
Entities:
Keywords:
Cellular functions of TERT; GBM; Glioblastoma; TERT promoter mutation (TPM); Telomerase reverse transcriptase (TERT); Therapeutic targeting of TERT
Authors: Ralph Salloum; Trent R Hummel; Shiva Senthil Kumar; Kathleen Dorris; Shaoyu Li; Tong Lin; Vinay M Daryani; Clinton F Stewart; Lili Miles; Tina Young Poussaint; Charles Stevenson; Stewart Goldman; Girish Dhall; Roger Packer; Paul Fisher; Ian F Pollack; Maryam Fouladi; James Boyett; Rachid Drissi Journal: J Neurooncol Date: 2016-06-27 Impact factor: 4.130
Authors: Josh Lewis Stern; Dan Theodorescu; Bert Vogelstein; Nickolas Papadopoulos; Thomas R Cech Journal: Genes Dev Date: 2015-10-29 Impact factor: 11.361
Authors: Meihua Luo; Leo Kit Cheung Lee; Bo Peng; Chung Hang Jonathan Choi; Wing Yin Tong; Nicolas H Voelcker Journal: Adv Sci (Weinh) Date: 2022-07-18 Impact factor: 17.521